The EU-ADR Web Platform: delivering advanced pharmacovigilance tools-Reference-Cited by-同舟云学术

The EU-ADR Web Platform: delivering advanced pharmacovigilance tools

Published:2012-12-04 Issue:5 Volume:22 Page:459-467
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Oliveira José Luis¹,Lopes Pedro¹,Nunes Tiago¹,Campos David¹,Boyer Scott²,Ahlberg Ernst²,van Mulligen Erik M.³,Kors Jan A.³,Singh Bharat³,Furlong Laura I.⁴,Sanz Ferran⁴,Bauer-Mehren Anna⁴,Carrascosa Maria C.⁴,Mestres Jordi⁴,Avillach Paul,Diallo Gayo⁵,Díaz Acedo Carlos⁶,van der Lei Johan³

Affiliation:

1. DETI/IEETA; University of Aveiro; Aveiro; Portugal

2. AstraZeneca; Molndal; Sweden

3. Erasmus University Medical Center; Rotterdam; The Netherlands

4. Research Programme on Biomedical Informatics (GRIB); IMIM Hospital del Mar Research Institute and Universitat Pompeu Fabra; Barcelona; Catalonia; Spain

5. LESIM-ISPED; Université de Bordeaux; Bordeaux; France

6. Synapse Research Management Partners; Barcelona; Spain

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference42 articles.

1. When good drugs go bad;Giacomini;Nature,2007

2. EMA Annual Report. European Medicines Agency 2010

3. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety;Robb;Pharmacoepidemiol Drug Saf,2012

4. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics;Xu;J Pharm Sci,2011

5. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data;Nelson;Pharmacoepidemiol Drug Saf,2012

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating duplication in pharmacovigilance databases: a scoping review;BMJ Open;2024-04

2. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years;Frontiers in Immunology;2023-03-16

3. Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: A cross-sectional analysis;Clinical Trials;2022-04-28

4. Standardizing registry data to the OMOP Common Data Model: experience from three pulmonary hypertension databases;BMC Medical Research Methodology;2021-11-02

5. Computer-Aided Pharmacoepidemiology in Drug Use and Safety: Examining the Intersection between Data Science and Medicines Research;New Insights into the Future of Pharmacoepidemiology and Drug Safety;2021-10-13